A big week for Ebola vaccines

Merck's Ebola vaccine gets approved while public health workers deploy Janssen's
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research

Related Links:

Swati Gupta ’97 M.P.H. and Anant Shah ’07 M.P.H. are at the forefront of the global fight against Ebola.
Source: Yale Science and Health News - Category: Universities & Medical Training Source Type: news
Recent occurrences of filoviruses and the arenavirus Lassa virus (LASV) in overlapping endemic areas of Africa highlight the need for a prophylactic vaccine that would confer protection against all of these viruses that cause lethal hemorrhagic fever (HF). We developed a quadrivalent formulation of VesiculoVax that contains recombinant vesicular stomatitis virus (rVSV) vectors expressing filovirus glycoproteins and that also contains a rVSV vector expressing the glycoprotein of a lineage IV strain of LASV. Cynomolgus macaques were vaccinated twice with the quadrivalent formulation, followed by challenge 28 days after the b...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
[New Times] Rwanda and the Democratic Republic of the Congo Sunday unveiled a massive vaccination campaign against Ebola Virus Disease (EVD) for their residents who live within the vicinity of a possible Ebola outbreak.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Up to 200,000 Regimens of Janssen ’s Investigational Ebola Vaccine to be Supplied to Rwanda for Use in Border Region near Democratic Republic of the Congo (DRC)
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
- A stockpile of 500,000 doses of Ebola vaccine for emergency use in outbreaks of the deadly fever is being established by the global vaccine alliance GAVI.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Vaccine alliance announces creation of Ebola vaccine stockpile of about 500,000 doses
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
[WHO] Kinshasa, 5 December 2019 - Around 2.2 million children are to be vaccinated against measles in North Kivu, the Democratic Republic of the Congo (DRC), where efforts are underway to curb the world's second-worst Ebola outbreak amid persistent insecurity.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
We report a candidate lead (compound #5: ((10R)-10-(4-hydroxyphenyl)-11,12,14,16-tetraazatetracyclo[7.7.0.02,7.011,15] hexadeca-1(16), 2(7),3,5,8,12,14-heptaen-8-ol)) with high drug-likeness score, promising lead-likeness behaviour and high median lethal dose. The candidate lead compound #5 engages in hydrogen bonding and hydrophobic interactions with VP40 active site residues. Thus, the lead compound #5 is recommended for further in vitro and in vivo validations for further consideration. PMID: 31787811 [PubMed]
Source: Bioinformation - Category: Bioinformatics Authors: Tags: Bioinformation Source Type: research
Condition:   Ebola Virus Disease Intervention:   Biological: Ad26.ZEBOV vaccine Sponsors:   Universiteit Antwerpen;   Johnson & Johnson;   Ace Africa;   Innovative Medicines Initiative;   Coalition for epidemic prepardness innovations;   University of Kinshasa Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
As the outbreak wanes, one vaccine has been approved and another has entered the next phase of testing
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
More News: Chemistry | Ebola | Ebola Vaccine | International Medicine & Public Health | Merck | Vaccines